GW&K Investment Management LLC Sells 10,947 Shares of Hologic, Inc. (NASDAQ:HOLX)

GW&K Investment Management LLC cut its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 2.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 529,864 shares of the medical equipment provider's stock after selling 10,947 shares during the period. GW&K Investment Management LLC owned approximately 0.24% of Hologic worth $32,729,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Raiffeisen Bank International AG bought a new position in shares of Hologic during the fourth quarter valued at about $49,000. Allworth Financial LP grew its position in Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after purchasing an additional 216 shares during the period. Larson Financial Group LLC grew its position in Hologic by 6,016.7% in the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 722 shares during the period. West Financial Advisors LLC purchased a new position in shares of Hologic during the 1st quarter worth $50,000. Finally, Covestor Ltd lifted its stake in shares of Hologic by 49.3% during the 4th quarter. Covestor Ltd now owns 1,033 shares of the medical equipment provider's stock valued at $75,000 after buying an additional 341 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Stock Performance

Shares of NASDAQ HOLX traded up $0.71 during midday trading on Friday, hitting $66.81. 319,398 shares of the company's stock were exchanged, compared to its average volume of 2,898,196. The firm has a market capitalization of $14.89 billion, a PE ratio of 28.18, a price-to-earnings-growth ratio of 2.42 and a beta of 0.55. The company's 50 day moving average price is $63.14 and its 200 day moving average price is $63.04. The company has a quick ratio of 2.52, a current ratio of 3.24 and a debt-to-equity ratio of 0.54. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The business had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. During the same quarter in the prior year, the firm earned $1.03 EPS. The business's revenue for the quarter was down 1.2% compared to the same quarter last year. As a group, analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on HOLX. Morgan Stanley cut their price target on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. Raymond James Financial restated an "outperform" rating and set a $71.00 price target (down previously from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Wall Street Zen downgraded shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Finally, Mizuho upped their target price on shares of Hologic from $65.00 to $70.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $77.33.

Insider Activity at Hologic

In related news, Director Martin D. Madaus purchased 5,445 shares of the business's stock in a transaction dated Wednesday, May 7th. The stock was purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the acquisition, the director directly owned 5,445 shares of the company's stock, valued at approximately $300,781.80. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.88% of the company's stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.